Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical Trials in STS Shreyaskumar Patel, M.D.

Published byJesko Kurzmann Modified over 5 years ago

Similar presentations

Presentation on theme: "Clinical Trials in STS Shreyaskumar Patel, M.D."— Presentation transcript:

1 Clinical Trials in STS Shreyaskumar Patel, M.D.
RR Herring Distinguished Professor of Medicine Center Medical Director, Sarcoma Center Deputy Chairman, Dept. of Sarcoma Medical Oncology Clinical Trials in STS Texas Medical Center Houston, Texas

2 What are Clinical trials?
Research investigations (experiments) designed meticulously to find “new agents” or “improve upon the current SOC” (dose, schedule, toxicities, relapse rate/time, survival, QOL…) “Phases” of drug development Preclinical – Drug screens, PDX, animal model Objective: Determine LD10 Clinical – Phase 1-4 (Human) Clinical Trials

3 Phase 1 trials Typically not cancer specific (exceptions e.g. targeted therapies), ~ patients Primary Objective is to determine the appropriate dose and schedule for humans (MTD, OBD) But, also provides some signal of efficacy in specific subsets

4 Phase 2 trials Typically VERY cancer specific (exceptions e.g. targeted therapies like NTRKi), ~ patients in a single-arm trial Primary Objective is to determine the efficacy and safety in humans Endpoints: Response rate, Clinical Benefit Rate, Progression-free survival Toxicities / side-effects

5 Phase 3 trials Typically randomized, VERY cancer specific, several hundred patients Primary Objective is to compare the efficacy and safety between new Rx and current SOC Endpoints: Survival, Progression-free survival, Response rate, QOL If indeed superior, new drug/regimen gets FDA approval for commercial use

6 Phase 4 trials Rarely mandated post marketing by FDA to collect more “real world experience” with side-effects/toxicity profile of the newly approved drug/regimen

7 How do I find out about Clinical trials in sarcomas
Seek consultation with a Sarcoma expert and ask him/her to guide you Appropriateness of a trial vs. SOC (E,T,C) Clinicaltrials.gov Foundations, Advocacy and Support Groups Websites of major cancer centers

8 Clinical Trials in STS Shreyaskumar Patel, M.D.
RR Herring Distinguished Professor of Medicine Center Medical Director, Sarcoma Center Deputy Chairman, Dept. of Sarcoma Medical Oncology Clinical Trials in STS Texas Medical Center Houston, Texas

Download ppt "Clinical Trials in STS Shreyaskumar Patel, M.D."

Similar presentations

Clinical Trials What Are They and When Are They Right For You? Maura N. Dickler Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering.

Clinical Trials What Are They and When Are They Right For You? Maura N. Dickler Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering.
Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.
A Proposal for BMS-354825 (Dasatinib) in GIST Jon Trent, MD, PhD Assistant Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson.

A Proposal for BMS (Dasatinib) in GIST Jon Trent, MD, PhD Assistant Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson.
Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
Modified Megestrol The Clinical Trials by : Carolina R. Akib

Modified Megestrol The Clinical Trials by : Carolina R. Akib
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.

Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.
Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.

Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Drug Development.

Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Drug Development.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center 1-13-04.

INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.

CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.
Phase II Trials in Oncology S. Gail Eckhardt, MD Lillian Siu, MD Brian I. Rini, M.D.

Phase II Trials in Oncology S. Gail Eckhardt, MD Lillian Siu, MD Brian I. Rini, M.D.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA.

Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA.
Stages of drug development

Stages of drug development
Drug Treatment of Metastatic Breast Cancer

Drug Treatment of Metastatic Breast Cancer
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
1 Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property Frank S. Castellana, M.D., Eng.Sc.D.

1 Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property Frank S. Castellana, M.D., Eng.Sc.D.
The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Similar presentations

Ads by Google